| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
103,650,000 |
| Market
Cap: |
1.52(B) |
| Last
Volume: |
926,334 |
Avg
Vol: |
1,686,438 |
| 52
Week Range: |
$11.5 - $17.51 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 604 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Catalyst Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing medicines for patients living with rare diseases. Co.'s primary product, Firdapse®, is used for the treatment of adult patients (ages 17 and above) with Lambert-Eaton, Myasthenic Syndrome, a rare autoimmune neuromuscular disorder characterized by muscle weakness of the limbs. Co. has developed its vigabatrin (CPP-109) as a generic version of Sabril®. Co. has an agreement with Endo International plc's subsidiary, Endo Ventures Limited, for the development and commercialization of generic Sabril® tablets through Endo's U.S. Generic Pharmaceuticals segment, Par Pharmaceutical.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
50,000 |
304,000 |
330,151 |
4,223,516 |
| Total Sell Value |
$803,000 |
$4,338,050 |
$4,684,028 |
$62,649,148 |
| Total People Sold |
2 |
6 |
7 |
12 |
| Total Sell Transactions |
2 |
8 |
9 |
53 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tierney David S |
Director |
– • – |
2024-04-08 |
4 |
S |
$15.68 |
$392,000 |
D/D |
(25,000) |
348,874 |
|
3% |
|
| Tierney David S |
Director |
– • – |
2024-04-08 |
4 |
OE |
$4.01 |
$100,250 |
D/D |
25,000 |
373,874 |
|
- |
|
| Elsbernd Brian |
Chief Compliance/Legal Officer |
• – – |
2024-03-27 |
4 |
S |
$16.44 |
$411,000 |
D/D |
(25,000) |
124,433 |
|
7% |
|
| Elsbernd Brian |
Chief Compliance/Legal Officer |
• – – |
2024-02-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,353) |
149,433 |
|
- |
|
| Elsbernd Brian |
Chief Compliance/Legal Officer |
• – – |
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,667 |
151,786 |
|
- |
|
| O'keeffe Charles B |
Director |
– • – |
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
685,724 |
|
- |
|
| Del Carmen Jeffrey |
Chief Commercial Officer |
• – – |
2024-02-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,125) |
25,968 |
|
- |
|
| Del Carmen Jeffrey |
Chief Commercial Officer |
• – – |
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,667 |
29,093 |
|
- |
|
| Sundaram Preethi |
Chief Strategy Officer |
• – – |
2024-02-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(6,025) |
25,541 |
|
- |
|
| Sundaram Preethi |
Chief Strategy Officer |
• – – |
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,667 |
31,566 |
|
- |
|
| Tierney David S |
Director |
– • – |
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
348,874 |
|
- |
|
| Ingenito Gary |
Chief Med. & Reg. Officer |
• – – |
2024-02-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,435) |
51,391 |
|
- |
|
| Ingenito Gary |
Chief Med. & Reg. Officer |
• – – |
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
53,826 |
|
- |
|
| Miller Steve |
Chief Op. & Scientific Officer |
• – – |
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,667 |
825,124 |
|
- |
|
| Harper Molly |
Director |
– • – |
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
5,333 |
|
- |
|
| Daly Richard J |
President and CEO |
• • – |
2024-02-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,186) |
212,147 |
|
- |
|
| Daly Richard J |
President and CEO |
• • – |
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
213,333 |
|
- |
|
| Denkhaus Donald A |
Director |
– • – |
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
438,333 |
|
- |
|
| Denkhaus Donald A |
Director |
– • – |
2024-02-05 |
4 |
OE |
$4.01 |
$160,400 |
D/D |
40,000 |
434,333 |
|
- |
|
| Mcenany Patrick J |
Chairman of Board of Directors |
– • – |
2024-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
143,000 |
4,528,256 |
|
- |
|
| Tierney David S |
Director |
– • – |
2024-01-02 |
4 |
OE |
$1.13 |
$11,300 |
D/D |
10,000 |
344,874 |
|
- |
|
| O'keeffe Charles B |
Director |
– • – |
2024-01-02 |
4 |
OE |
$1.13 |
$67,800 |
D/D |
60,000 |
681,724 |
|
- |
|
| Mcenany Patrick J |
Chairman of Board of Directors |
– • – |
2024-01-02 |
4 |
OE |
$1.13 |
$282,500 |
D/D |
250,000 |
4,385,256 |
|
- |
|
| Denkhaus Donald A |
Director |
– • – |
2023-12-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,333 |
394,333 |
|
- |
|
| Sundaram Preethi |
Chief Strategy Officer |
• – – |
2023-12-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,409) |
14,899 |
|
- |
|
434 Records found
|
|
Page 1 of 18 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.44 (2.91%) 
